- income derived from Clarion (some numbers)............... Not until the first qtyly after patents have begin therapy. This could be 2nd quarter.
- a cap raise........................................Not at this level of liquidity. I would assume a major push in developments leading into a raising.
Next lot of news
Near term;
*Updated and the RePosa TP2B3 site approvals and accepting patents.
*Analytic report and TP2 PSIGAD
*Pre IND/FDA feed back on PSIGAD TP2B for the US
*Updates on CannQuit N trials
*Mr Robert Clark's package updates. Assume that this package will be re-negotiated.
*Possibly;
675A interim data. Early H2
Regulatory developments in Europe for the RePosa trials.
Regulatory developments in UK for PSIGAD trials.
CannQuit O. Bigger TAM than CannQuit N. (Having 4 trials might be a tall order with available COH)
Clarion updates and Qtrly. Late H2
Hopefully;
Once Analytic PSIGAD report, patent intake with Reposa TP2B3, CannQuit N updates and positive PSI TP2B FDA feedback a new and updated presentation squarely focused on the US market focusing on late stage drug developments and benchmarks. Commencing RePosa TP2B3 will be a huge milestone for Incannex bring IHL-42X our first drug/compound asset squarely into late stage development. A big tick for the US investors.
GL @Slyau90
- Forums
- ASX - By Stock
- IHL
- General discussion
General discussion, page-19515
- There are more pages in this discussion • 364 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non Executive Director
Simon Kidston
Non Executive Director
SPONSORED BY The Market Online